Clinical Trials Directory

Trials / Completed

CompletedNCT04184258

Treatment of Systemic Lupus Erythematosus With Pooled Allogenic Mesenchymal Stem Cells

Treatment of Systemic Lupus Erythematosus With Pooled Allogenic Olfactory Mucosa Derived Mesenchymal Stem Cells

Status
Completed
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
7 (actual)
Sponsor
Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus · Other Government
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

Treatment of systemic lupus erythematosus with pooled allogenic mesenchymal stem cells

Conditions

Interventions

TypeNameDescription
BIOLOGICALPooled mesenchymal stem cellPooled allogenic mesenchymal stem cell derived from olfactory mucosa
OTHERStandard treatment according to the Clinical protocolsStandard SLE treatment according to the Clinical protocols approved by the Ministry of healthcare of Republic of Belarus

Timeline

Start date
2019-07-01
Primary completion
2020-12-31
Completion
2020-12-31
First posted
2019-12-03
Last updated
2021-01-22

Locations

1 site across 1 country: Belarus

Source: ClinicalTrials.gov record NCT04184258. Inclusion in this directory is not an endorsement.

Treatment of Systemic Lupus Erythematosus With Pooled Allogenic Mesenchymal Stem Cells (NCT04184258) · Clinical Trials Directory